Testimonies & Filings

May 16, 2019
ITIF endorses USTR’s proposed imposition of countermeasures, in the form of additional tariffs, commensurate with what the WTO’s Dispute Settlement Body has found to be adverse effects inflicted on U.S. aerospace competitors as a result of the EU’s WTO-inconsistent subsidy programs for large civil aircraft.
May 16, 2019
In testimony before the House Oversight Committee, Stephen Ezell explained why the United States leads the world in life-sciences innovation; how the public and private sectors contribute; why innovation depends on the ability to generate revenues; the consequences of price controls; and how best to control health-care costs.
May 15, 2019
In testimony before the Senate Small Business and Entrepreneurship Committee, Stephen Ezell highlighted the successes of federal small business programs directed toward innovation research and technology transfer and argued there is much more to be done to promote technology transfer and commercialization.
March 8, 2019
In a filing with India’s Department for Promotion of Industry and Internal Trade, ITIF argued that a misguided focus on the control and location of data will reduce its potential social and economic utility.
March 8, 2019
ITIF has filed comments with the California Attorney General regarding its preliminary rulemaking process for the California Consumer Privacy Act. ITIF argues the Attorney General should clarify its rules to minimize their burden on innovation.
February 27, 2019
Rob Atkinson testified before the Senate Small Business Committee on the issue of unfair Chinese trade and technology policies and practices and what the federal government should do in response.
February 13, 2019
In testimony before the House Energy & Commerce Subcommittee on Communications and Technology, Doug Brake spoke in favor of the T-Mobile and Sprint merger on the grounds that it would bring about a better future for American businesses and consumers compared to one where each company attempted to continue alone.
February 8, 2019
ITIF has filed comments with the U.S. Consumer Financial Protection Bureau (CFPB), regarding its proposed rules for no-action letters and the product sandbox. CFPB should use these policies to facilitate experimentation in financial services.
January 24, 2019
ITIF signed a coalition letter, led by the Competitive Enterprise Institute, urging Congress to prioritize restoring the longstanding users-pay/users-benefit principle in the Highway Trust Fund.
December 31, 2018
Adopting an international drug reference pricing scheme would limit drug innovation—potentially leading to higher, not lower, health care costs in the future—while at the same time reducing U.S. biopharmaceutical industry competitiveness, meaning fewer jobs and exports.

Pages